Australian Pharmaceuticals & Biotech Top Stock Picks from Analysts

Mesoblast

Market Cap: AU$2.2b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Neuren Pharmaceuticals

Market Cap: AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Opthea

Market Cap: AU$738.8m

A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

Clarity Pharmaceuticals

Market Cap: AU$707.0m

A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.

PYC Therapeutics

Market Cap: AU$699.9m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Botanix Pharmaceuticals

Market Cap: AU$696.1m

Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.

Clinuvel Pharmaceuticals

Market Cap: AU$532.6m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Immutep

Market Cap: AU$430.8m

A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Mayne Pharma Group

Market Cap: AU$391.6m

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Race Oncology

Market Cap: AU$246.7m

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.

Aroa Biosurgery

Market Cap: AU$155.2m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Trajan Group Holdings

Market Cap: AU$137.9m

Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.

Genetic Signatures

Market Cap: AU$130.6m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Imugene

Market Cap: AU$126.9m

A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Paradigm Biopharmaceuticals

Market Cap: AU$122.7m

Engages in the research and development of therapeutic products for human use in Australia.

Syntara

Market Cap: AU$108.8m

Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia.

Alterity Therapeutics

Market Cap: AU$91.3m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Arovella Therapeutics

Market Cap: AU$88.8m

A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.

Recce Pharmaceuticals

Market Cap: AU$76.0m

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

EZZ Life Science Holdings

Market Cap: AU$71.0m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.

Medical Developments International

Market Cap: AU$69.8m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

Neurizon Therapeutics

Market Cap: AU$66.5m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally.

Radiopharm Theranostics

Market Cap: AU$49.0m

Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.

Island Pharmaceuticals

Market Cap: AU$45.2m

A drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America.

Cynata Therapeutics

Market Cap: AU$44.1m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Little Green Pharma

Market Cap: AU$31.9m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

Acrux

Market Cap: AU$9.4m

Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

Cambium Bio

Market Cap: AU$3.5m

A clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications.